tbuckley/cabot-search huggingface dataset:
Effect of inspiratory flow rate on respiratory sensation and pattern of breathing.
Authors: H L Manning, E J Molinary, J C Leiter
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

We examined the effect of inspiratory flow rate (IFR) on respiratory sensation during mechanical ventilation in 10 normal subjects. We adjusted the ventilator tidal volume (VT), frequency, and IFR until subjects indicated that they were maximally comfortable ("comfort IFR"). Subjects then rated breathing discomfort on a visual analog scale (VAS) while IFR was varied among four levels: 70%, 100%, 200%, and 300% of the comfort IFR. When compared with VAS ratings at the comfort IFR (4.4 +/- 1.2, mean +/- SEM), VAS ratings were significantly greater at the lowest (i.e., 70% comfort; 12.1 +/- 2.1) and highest (300% comfort; 8.2 +/- 0.9) IFR; there was no difference in ratings between the comfort IFR and 200% comfort IFR. At the lowest IFR, the breathing discomfort arose in the chest and had an air hunger-like quality; at high IFR, the discomfort arose in the upper airway. In the second portion of the study, subjects used open magnitude estimation to rate breaths of five different sizes at three different IFR (70%, 100%, and 200% of comfort rate). Neither the exponent nor intercept for VT perception differed among the three IFR. Our results demonstrate that although IFR does not alter magnitude estimation of breath size, deviations of IFR from that desired by the subject may greatly affect respiratory comfort.
ROENTGENOLOGY OF TUBERCULOUS ENTEROCOLITIS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sudden onset of headache, proptosis, and roaring tinnitus in a hypertensive 60-year-old woman
Authors: E. J. Russell
Journal: JAMA (1983)

<h3>History</h3> A mildly hypertensive 60-year-old woman experienced an acute throbbing right frontal headache, right partial ptosis, and an audible roar centered at the right ear. During the next 12 hours, the eye became red and proptotic and finally closed. The patient gave no history of trauma. On physical examination, BP was 120/70 mm Hg and the pulse rate was 60 beats per minute and regular. Vision was normal in the right eye, but ptosis, subconjunctival hemorrhage, and chemosis were present. The right pupil was dilated and nonreactive to light. A complete third-nerve palsy was noted. Ophthalmoscopic examination gave normal findings. A roaring bruit was heard over the right side of the skull; it was best heard at the right orbit. Cerebral angiography was performed on the day of admission (Fig 1, top and bottom left), and definitive treatment was instituted six days later. <h3>Diagnosis</h3> Spontaneous carotid-cavernous fistula. The diagnosis was
Thyroid-Antithyroid Treatment of Hyperthyroidism
Authors: Leonard Wartofsky
Journal: JAMA (1971)

<h3>To the Editor.—</h3> Selenkow in a recent letter (<b>214</b>:2198,1970) chides Green (<b>213</b>:1652, 1970) for his choice of Dr. John Eager Howard as a supporting reference for the use of thyroid-antithyroid combination therapy in hyperthyroidism (<b>202</b>: 706-709, 1967). In fairness to Dr. Green, his statement simply referred to "other physicians" who "routinely give thyroid with PTU [propylthiouracil]," and was clearly not intended to annotate the literature. Likewise, one should not allude to Howard's statement out of context, in that the informal discussion of the quoted lecture was intended neither to be encyclopedic, nor to take credit for the initial advocacy of such a treatment program. Further, I must take issue with Selenkow's recommendation of this combined therapy in all patients selected for antithyroid treatment. This is still an area of controversy even among eminent thyroidologists, and it may be grossly misleading to the practicing physician for someone of Selenkow's
National survey of notifications of tuberculosis in England and Wales in 1988. Medical Research Council Cardiothoracic Epidemiology Group.
Authors: S Meredith, V Aber, A Nunn, D Johnson, J Darbyshire
Journal: Thorax (1992)

A survey was undertaken to determine the distribution of tuberculosis in England and Wales and, by comparison with the findings of similar surveys in 1978-9 and 1983, to study trends in the incidence of the disease by ethnic group over the decade.The survey included all cases of tuberculosis in England and Wales newly notified to the medical officers for environmental health during the six months from 2 January to 1 July 1988. Notification rates were calculated from population estimates from the 1988 Labour Force Survey.Clinical details were obtained from the clinician for 2149 (99.4%) of the 2163 newly notified and previously untreated patients. Over 90% were either white (53%) or of Indian, Pakistani, or Bangladeshi ethnic origin (39%). The notification rate in the white population was 4.7/100,000/year, a decline of 7.2% per year since 1978. The rate was 134.6/100,000/year in the population of Indian ethnic origin, and 100.5/100,000/year in that of Pakistani or Bangladeshi ethnic origin, a decline of 6% a year since 1978 for the two groups combined (standardised for age, country of birth, and length of time in the UK). In all ethnic groups rates of disease were much higher in the elderly than in the young. Bacteriological results were available in 1161 (80%) of the 1443 pulmonary cases. In 939 (81%) Mycobacterium tuberculosis was cultured; 614 cases (53%) also had positive smears, of which 424 (69%) were from white patients.Notification rates for tuberculosis in England and Wales declined over the decade, but major differences remained between ethnic groups.
BUDAPEST
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Female Sex Hormone. Part I: Biology, Pharmacology and Chemistry. Part II: Clinical Investigations Based on the Female Sex Hormone Blood Test.
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Date in Figure Title
Authors: Nikhil Dhurandhar, Diana Thomas
Journal: JAMA (2015)

Eyal Leshem, MD; Jacqueline E. Tate, PhD; Claudia A. Steiner, MD, MPH; Aaron T. Curns, MPH; Ben A. Lopman, PhD; Umesh D. Parashar, MBBS, MPH
Phase 1b study of selinexor, a first in class selective inhibitor of nuclear export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).
Authors: Eoghan Ruadh Malone, Esmail al-Ezzi, Abha A. Gupta, Pernille Pedersen, Dagmara Kolodziejczyk, Ragitha Ellencherry, Oulu Zhu, Albiruni Ryan Abdul Razak, Jeremy Howard Lewin
Journal: Journal of Clinical Oncology (2018)

11562 Background: Selinexor is a first-in-class SINE compound with single-agent activity in STS. We undertook this study to determine the safety, tolerability and efficacy of selinexor when combined with doxorubicin in pts with locally advanced or metastatic STS. Methods: This phase 1b study was conducted using a modified toxicity probability index (mTPI) design. Patients with locally advanced or metastatic STS received selinexor at two dose levels (60 or 80mg weekly PO) plus doxorubicin (75mg/m2 IV q21 days, max 6 cycles). Pts with stable disease or better (per RECIST 1.1 criteria) after 6 cycles of combination treatment received selinexor monotherapy until disease progression or unacceptable toxicity. Disease assessments were made with standard imaging after every 2 cycles. Limited pharmacokinetic (PK) data was collected for the first 3 pts at each dose level. Results: 13 pts (11F/2M, ECOG 0/1: 5/8, median age 63 years [range 51-73]) were enrolled. Disease subtypes included leiomyosarcoma (n = 6), undifferentiated pleomorphic sarcoma (n = 2; UPS), liposarcoma (n = 2) and other sarcomas (n = 3). Three pts at 60mg selinexor and 10 pts at 80mg selinexor have been treated. The most common G3 drug related adverse events (AEs) were hematological, including neutropenia n = 6 (46%), anemia n = 3 (23%). There were two dose-limiting toxicities (febrile neutropenia and unresolved fatigue lasting more than 7 days), both at the 80mg dose level. Of the 13 evaluable pts (median follow-up of 15 weeks [range 5-31]), partial response was seen in 3 pts (23%, n = 1 for UPS, malignant peripheral nerve sheath tumor and myxofibrosarcoma) and stable disease was seen in 7 (54%). PK analysis of selinexor did not demonstrate changes compared to single agent profile. Conclusions: Our initial data demonstrate that the combination of selinexor and doxorubicin appears to be tolerable and safe. There was no exposure changes oberserved for selinexor in this combination regimen. Updated toxicity, safety and efficacy data will be presented at the meeting. Clinical trial information: NCT03042819.
LEUKOPLAKIA BUCCALIS
Authors: H. H. HAZEN
Journal: JAMA (1922)

Many irritants seem to produce cancer.The injection of scarlet red, and, recently, the application of coal tar have been found regu¬ larly .tocause cancer.While irritation undoubtedly has much to do with the etiology of cancer, certain regions of the body, where irritation is more likely to occur than on any other part of the body, seem to be practically immune from cancer.I have never seen a cancer of the palm of the hand, for instance.Dr. Ochsner's theories about parasites being the cause of cancer are interesting.He thinks that a parasite that produces cancer is present in human excrement.The obvious objection to this theory, however, is that if these parasites are present in the human excrement, cancer
Sickle Cell Disease Screening Offers Educational Opportunity for Parents
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Standards for Measures Used for Public Reporting of Efficiency in Health Care
Authors: Harlan M. Krumholz, Patricia S. Keenan, John E. Brush, Vincent J. Bufalino, Michael E. Chernew, Andrew J. Epstein, Paul A. Heidenreich, Vivian Ho, Frederick A. Masoudi, David B. Matchar, Sharon-Lise T. Normand, John S. Rumsfeld, Jeremiah D. Schuur, Sidney C. Smith, John A. Spertus, Mary Norine Walsh
Journal: Circulation (2008)

The assessment of medical practice is evolving rapidly in the United States. An initial focus on structure and process performance measures assessing the quality of medical care is now being supplemented with efficiency measures to quantify the “value” of healthcare delivery. This statement, building on prior work that articulated standards for publicly reported outcomes measures, identifies preferred attributes for measures used to assess efficiency in the allocation of healthcare resources. The attributes identified in this document combined with the previously published standards are intended to serve as criteria for assessing the suitability of efficiency measures for public reporting. This statement identifies the following attributes to be considered for publicly reported efficiency measures: integration of the quality and cost; valid cost measurement and analysis; minimal incentive to provide poor quality care; and proper attribution of the measure. The attributes described in this statement are relevant to a wide range of efforts to profile the efficiency of various healthcare providers, including hospitals, healthcare systems, managed-care organizations, physicians, group practices, and others that deliver coordinated care.
Incorrect Source of Data Cited
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients
Authors: Deepti Malhotra, Rajesh K. Thimmulappa, Nicolas Mercado, Kazuhiro Ito, Ponvijay Kombairaju, Sarvesh Kumar, Jinfang Ma, David Feller-Kopman, Robert Wise, Peter Barnes, Shyam Biswal
Journal: Journal of Clinical Investigation (2014)

The JCI, with the agreement of the corresponding authors and coauthors, is retracting the article "Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients."The IP: streptavidin/IB: anti-HDAC2 immunoblot panel in Figure 3B was recently identified as an inverted image of the right four lanes of the anti-H4 acetyl CHIP gel presented in Figure 2A.Additionally, the IP: anti-streptavidin/IB: anti-DDK immunoblot presented in Supplemental Figure 3A was identified as an inverted image of the left four lanes of the anti-H4 acetyl CHIP gel presented in Figure 2A.Further, in Figure 9B, the incorrect anti-HDAC2 immuno blot was presented.
Emergency Planning and the Acute Toxic Potency of Inhaled Ammonia
Authors: Robert A. Michaels
Journal: Environmental Health Perspectives (1999)

Ammonia is present in agriculture and commerce in many if not most communities. This report evaluates the toxic potency of ammonia, based on three types of data: anecdotal data, in some cases predating World War 1, reconstructions of contemporary industrial accidents, and animal bioassays. Standards and guidelines for human exposure have been driven largely by the anecdotal data, suggesting that ammonia at 5,000-10,000 parts per million, volume/volume (ppm-v), might be lethal within 5-10 min. However, contemporary accident reconstructions suggest that ammonia lethality requires higher concentrations. For example, 33,737 ppm-v was a 5-min zero-mortality value in a major ammonia release in 1973 in South Africa. Comparisons of secondary reports of ammonia lethality with original sources revealed discrepancies in contemporary sources, apparently resulting from failure to examine old documents or accurately translate foreign documents. The present investigation revealed that contemporary accident reconstructions yield ammonia lethality levels comparable to those in dozens of reports of animal bioassays, after adjustment of concentrations to human equivalent concentrations via U.S. Environmental Protection Agency (EPA) procedures. Ammonia levels potentially causing irreversible injury or impairing the ability of exposed people to escape from further exposure or from coincident perils similarly have been biased downwardly in contemporary sources. The EPA has identified ammonia as one of 366 extremely hazardous substances subject to community right-to-know provisions of the Superfund Act and emergency planning provisions of the Clean Air Act. The Clean Air Act defines emergency planning zones (EPZs) around industrial facilities exceeding a threshold quantity of ammonia on-site. This study suggests that EPZ areas around ammonia facilities can be reduced, thereby also reducing emergency planning costs, which will vary roughly with the EPZ radius squared.
Steroid Hormones and Brain Development: Some Guidelines for Understanding Actions of Pseudohormones and Other Toxic Agents
Authors: Bruce S. McEwen
Journal: Environmental Health Perspectives (1987)

Gonadal, adrenal, and thyroid hormones affect the brain directly, and the sensitivity to hormones begins in embryonic life with the appearance of hormone receptor sites in discrete populations of neurons. Because the secretion of hormones is also under control by its neural and pituitary targets, the brain-endocrine axis during development is in a delicately balanced state that can be upset in various ways, and any agent that disrupts normal hormone secretion can upset normal brain development. Moreover, exogenous substances that mimic the actions of natural hormones can also play havoc with CNS development and differentiation. This paper addresses these issues in the following order: First, actions of glucocorticoids on the developing nervous system related to cell division dendritic growth and neurotransmitter phenotype will be presented followed by a discussion of the developmental effects of synthetic steroids. Second, actions of estrogens related to brain sexual differentiation will be described, followed by a discussion of the actions of the nonsteroidal estrogen, diethylstilbestrol, as an example of exogenous estrogenic substances. The most important aspect of the potency of exogenous estrogens appears to be the degree to which they either bypass protective mechanisms or are subject to transformations to more active metabolites. Third, agents that influence hormone levels or otherwise modify the neuroendocrine system, such as nicotine, barbiturates, alcohol, opiates, and tetrahydrocannabinol, will be noted briefly to demonstrate the diversity of toxic agents that can influence neural development and affect personality, cognitive ability, and other aspects of behavior.(ABSTRACT TRUNCATED AT 250 WORDS)
Health evaluation of energy-generating sources. AMA Council on Scientific Affairs
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal